Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Parkinson's Disease
Interventions
DEVICE

tDCS

tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.

Trial Locations (1)

20007

MedStar Georgetown University Hospital, Washington D.C.

All Listed Sponsors
collaborator

Ferrell Family Charitable Foundation

UNKNOWN

lead

Georgetown University

OTHER

NCT02104401 - Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood | Biotech Hunter | Biotech Hunter